WASHINGTON, June 27 /PRNewswire/ -- Jim Greenwood, President & CEO of
the Biotechnology Industry Organization (BIO), announced today that after
12 years of dedicated service and leadership on behalf of the industry's
small and medium-sized companies, Morrie Ruffin, Executive Vice President
for Emerging Companies and Business Development, will leave the
organization on June 30 to pursue a career in strategic consulting. Mr.
Ruffin announced his intention to leave the organization to BIO's Emerging
Companies Section Governing Body at their meeting in April and agreed to
stay until a successor was identified.
Ruffin will join LifeTech Innovations (LTI,
http://www.lifetechresearch.com), a biotech and medtech strategic
consulting firm based in Washington, D.C. and Baltimore, MD, as CEO.
"Morrie was the architect of BIO's business development franchise and
has been a tireless proponent for BIO's emerging companies during his many
years at BIO. His knowledge about the industry and capital formation issues
will be greatly missed," Greenwood stated. "BIO looks forward to continuing
our relationship with Morrie as a consultant."
Greenwood also announced that Alan F. Eisenberg, BIO's Executive Vice
President for Advocacy, Operations, & Communications, will assume Ruffin's
responsibilities.
"Alan brings a wealth of public policy expertise and familiarity with
our membership to this position," Greenwood stated. "He will provide
tremendous energy and acumen to move BIO's advocacy forward on behalf of
our smaller companies and will do an outstanding job leading the staff and
service operations for the 800+ companies and organizations in our Emerging
Companies Section."
In his present position, Eisenberg oversees BIO's communications, state
government relations and Board operations, and coordinates BIO's advocacy
activities. Before joining BIO, Eisenberg served as a senior advisor on
health and economics policy for Greenwood during his Congressional tenure.
In this role, Eisenberg was extensively involved in the enactment of
numerous public laws including the Medical Device User Fee and
Modernization Act (P.L. 107-250) and the Best Pharmaceuticals for Children
Act (P.L. 107-109).
Previously, Eisenberg worked as a health policy advisor for the Senate
Health, Education, Labor and Pensions Subcommittee on Public Health and as
a legislative assistant for Congressman John Shadegg (AZ). Before coming to
Washington, Eisenberg worked for Ford Motor Company in Dearborn, MI, as a
research economist specializing in tax and regulatory issues and as a
finance manager in manufacturing.
Eisenberg holds a Master of Public Policy degree from Harvard
University and a Master of Science in Finance degree from George Washington
University.
BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations across
the United States and 31 other nations. BIO members are involved in the
research and development of healthcare, agricultural, industrial and
environmental biotechnology products.
SOURCE Biotechnology Industry Organization
 back to top
Related links:
http://www.bio.org
CONTACT:
Stephanie Fischer of Biotechnology Industry
Organization, +1-202-312-9263
|
